259 related articles for article (PubMed ID: 15634264)
1. Pleiotropic functions of plasminogen activator inhibitor-1.
Lijnen HR
J Thromb Haemost; 2005 Jan; 3(1):35-45. PubMed ID: 15634264
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinases and cellular fibrinolytic activity.
Lijnen HR
Biochemistry (Mosc); 2002 Jan; 67(1):92-8. PubMed ID: 11841344
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling.
Stefansson S; McMahon GA; Petitclerc E; Lawrence DA
Curr Pharm Des; 2003; 9(19):1545-64. PubMed ID: 12871067
[TBL] [Abstract][Full Text] [Related]
5. Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.
Whitley BR; Church FC
Int J Oncol; 2005 Sep; 27(3):749-57. PubMed ID: 16077925
[TBL] [Abstract][Full Text] [Related]
6. Conversion of plasminogen activator inhibitor-1 from inhibitor to substrate by point mutations in the reactive-site loop.
Audenaert AM; Knockaert I; Collen D; Declerck PJ
J Biol Chem; 1994 Jul; 269(30):19559-64. PubMed ID: 8034724
[TBL] [Abstract][Full Text] [Related]
7. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
[TBL] [Abstract][Full Text] [Related]
8. Plasminogen activator inhibitor-1 in kidney pathology (Review).
Małgorzewicz S; Skrzypczak-Jankun E; Jankun J
Int J Mol Med; 2013 Mar; 31(3):503-10. PubMed ID: 23314920
[TBL] [Abstract][Full Text] [Related]
9. [Role of PAI-1 plasminogen activator inhibitor in tumor invasion and angiogenesis].
Bajou K
Bull Mem Acad R Med Belg; 2002; 157(5-6):313-8. PubMed ID: 12557575
[TBL] [Abstract][Full Text] [Related]
10. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator.
Declerck PJ; De Mol M; Vaughan DE; Collen D
J Biol Chem; 1992 Jun; 267(17):11693-6. PubMed ID: 1601844
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and biophysical studies of reactive center cleaved plasminogen activator inhibitor type 1. The distance between P3 and P1' determined by donor-donor fluorescence energy transfer.
Aleshkov SB; Fa M; Karolin J; Strandberg L; Johansson LB; Wilczynska M; Ny T
J Biol Chem; 1996 Aug; 271(35):21231-8. PubMed ID: 8702896
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice.
Carmeliet P; Moons L; Lijnen R; Janssens S; Lupu F; Collen D; Gerard RD
Circulation; 1997 Nov; 96(9):3180-91. PubMed ID: 9386191
[TBL] [Abstract][Full Text] [Related]
13. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion.
Sharp AM; Stein PE; Pannu NS; Carrell RW; Berkenpas MB; Ginsburg D; Lawrence DA; Read RJ
Structure; 1999 Feb; 7(2):111-8. PubMed ID: 10368279
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms.
Debrock S; Declerck PJ
Biochim Biophys Acta; 1997 Feb; 1337(2):257-66. PubMed ID: 9048903
[TBL] [Abstract][Full Text] [Related]
15. A Narrative Review on Plasminogen Activator Inhibitor-1 and Its (Patho)Physiological Role: To Target or Not to Target?
Sillen M; Declerck PJ
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33800359
[TBL] [Abstract][Full Text] [Related]
16. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis.
Leik CE; Su EJ; Nambi P; Crandall DL; Lawrence DA
J Thromb Haemost; 2006 Dec; 4(12):2710-5. PubMed ID: 17010152
[TBL] [Abstract][Full Text] [Related]
17. The structural basis for the pathophysiological relevance of PAI-I in cardiovascular diseases and the development of potential PAI-I inhibitors.
Gils A; Declerck PJ
Thromb Haemost; 2004 Mar; 91(3):425-37. PubMed ID: 14983217
[TBL] [Abstract][Full Text] [Related]
18. PAI-1, progress in understanding the clinical problem and its aetiology.
Iwaki T; Urano T; Umemura K
Br J Haematol; 2012 May; 157(3):291-8. PubMed ID: 22360729
[TBL] [Abstract][Full Text] [Related]
19. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects.
Reilly TM; Mousa SA; Seetharam R; Racanelli AL
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):73-81. PubMed ID: 8180342
[TBL] [Abstract][Full Text] [Related]
20. [From fibrinogen to fibrin and its dissolution].
Juhan-Vague I; Hans M
Bull Acad Natl Med; 2003; 187(1):69-82; discussion 83-4. PubMed ID: 14556455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
